Ted Buchan & Co Purchases New Stake in Novo Nordisk A/S $NVO

Ted Buchan & Co acquired a new position in Novo Nordisk A/S (NYSE:NVO) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 27,503 shares of the company’s stock, valued at approximately $1,526,000.

Several other institutional investors have also recently added to or reduced their stakes in NVO. True Wealth Design LLC lifted its position in shares of Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after buying an additional 300 shares during the last quarter. Guerra Advisors Inc acquired a new stake in Novo Nordisk A/S during the third quarter worth about $25,000. Strengthening Families & Communities LLC bought a new position in Novo Nordisk A/S in the third quarter worth about $30,000. NewSquare Capital LLC boosted its stake in Novo Nordisk A/S by 174.1% in the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after acquiring an additional 282 shares during the period. Finally, Allianz SE grew its holdings in shares of Novo Nordisk A/S by 70.0% during the third quarter. Allianz SE now owns 578 shares of the company’s stock valued at $32,000 after purchasing an additional 238 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 0.3%

NYSE:NVO opened at $37.50 on Friday. The stock has a market cap of $167.42 billion, a price-to-earnings ratio of 10.81 and a beta of 0.67. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. Novo Nordisk A/S has a 1 year low of $37.31 and a 1 year high of $91.90. The business has a fifty day moving average of $52.75 and a 200-day moving average of $52.87.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The firm had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. Equities analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Announces Dividend

The business also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a dividend of $1.2751 per share. This represents a dividend yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 23.63%.

Analysts Set New Price Targets

Several brokerages recently issued reports on NVO. TD Cowen reissued a “buy” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 3rd. Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Citigroup initiated coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 27th. They set a “neutral” rating for the company. Nordea Equity Research cut shares of Novo Nordisk A/S to a “hold” rating in a report on Tuesday. Finally, The Goldman Sachs Group reiterated a “buy” rating on shares of Novo Nordisk A/S in a research report on Thursday, January 22nd. Six analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S has an average rating of “Hold” and an average target price of $56.07.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Large Vivtex collaboration expands Novo’s push into oral obesity/diabetes medicines, which could widen patient access and reduce dependency on injectables — a long‑term growth signal. Novo Nordisk Pipelines Oral Obesity Drugs
• Positive Sentiment: Strong phase‑2 China data for triple‑agonist UBT251 (nearly ~20% weight loss reported) supports Novo’s broader pipeline beyond GLP‑1 and bolsters future product optionality. China UBT251 Trial
• Positive Sentiment: Several bullish commentary pieces argue the sell‑off overstates fundamental damage: oral Wegovy adoption and expanded Medicare coverage are cited as durable demand drivers and cash‑flow support. Why I’m Still Bullish On Novo
• Neutral Sentiment: Short interest fell meaningfully in February, reducing one immediate source of potential downside pressure (fewer forced covers), but overall market sentiment remains mixed.
• Neutral Sentiment: Broader market rotation into defensive names and sector dynamics are influencing trading — Novo’s large market cap and dividend yield make it sensitive to flows unrelated to biotech fundamentals.
• Negative Sentiment: Multiple analyst downgrades and lowered price targets this week prompted selling and contributed directly to intraday weakness; investors are focused on near‑term U.S. price compression and margin implications. Analyst Downgrade — American Banking News
• Negative Sentiment: Pomerantz law‑firm investor alert / investigation increases legal risk and uncertainty for shareholders, which typically depresses sentiment until clarity arrives. Pomerantz Investor Alert
• Negative Sentiment: Market reaction shows concern that large deals (Vivtex) and pipeline expansion may pressure near‑term margins and raise execution questions — some headlines explicitly note the stock dipped after the Vivtex announcement. Stock Dipped After Vivtex Deal

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.